Skip to content
drillr.ai

AURA

Aura Biosciences, Inc.

NASDAQ · USHealthcareBiotechnology
$6.82-2.43%

Price as of Jul 20, 2026

AURA news

Aura Biosciences, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors

    BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (https://www.globenewswire.com/Tracker?data=8b0MCqn2fmRZWdbwn4j2QufQaCYC3WSP4voMop-Izf8e4GhZUZ7z-7Sa-fleDX3W4PQy19N66AbevrSCoB_GCBdbkvx3sOXQK4qifQgMtTlnsO7cCbp6JKThg69wO0OM) (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. “I am thrilled to welcome Je

    Globe Newswire ·

  2. Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (https://www.globenewswire.com/Tracker?data=0Oi_icZE31LdFVNj18KIKH00SfIHMrsM7j1IbOz7JxHMebHCvFeLGykvYQF1byrDOx0ZhZzjJRrVQFt2qh35B5VHSje4IWZ2711XjMc1-AOpzeThysMi_vfWl0OOVECu) (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted t

    Globe Newswire ·

  3. Aura Biosciences to Participate in Upcoming Investor Conferences

    BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (https://www.globenewswire.com/Tracker?data=epJ_6n4KzuW5Vn8jW1W5fOWIcmEHZGWKehEJx6t0yn586ybZ6jGWrRcv3VH3tlj8Upa76kAooxwEktHCiGT2GxyLEHVLMSHnsKHlZAORtcZSdkT-inA1rxW3doCQiVVC) (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences

    Globe Newswire ·

  4. Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

    Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance sheet with oversubscribed $299 million equity financing; cash position expected to fund operations into 2H 2028 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (https://www.globenewswire.com/Tracker?data=Son4oboSCVCnQFtYlaAMULfpFr_Jw77zb23l6H-mqU7cGAsAlkb_lzO_Zuhlky

    Globe Newswire ·

  5. Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

    BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the closing of its previously announced underwritten public offering. In the offering, Aura sold (i) 46,099,650 shares of common stock, which includes 6,508,650 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common

    Globe Newswire ·

  6. Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

    BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 39,591,000 shares of its common stock and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3,800,000 shares of its common stock at an exercise price o

    Globe Newswire ·

  7. Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

    BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Aura intends to grant the underwriters a 30-day option to purchase up to an

    Globe Newswire ·

  8. Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

    Natalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointed Chief Executive Officer and President and member of the Board of Directors Acceleration in patient screening driving Phase 3 CoMpass trial enrollment to near completion BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ funct

    Globe Newswire ·

  9. Auranova Resources and Kenorland Minerals Announce Completion of Spring Drill Program at the South Uchi Project, Ontario

    Vancouver, British Columbia--(Newsfile Corp. - April 28, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") and Kenorland Minerals Ltd. ("Kenorland") are pleased to announce the completion of the 2026 spring drill program at the South Uchi Project (the "Project"), located in the Red Lake District of Ontario. 2026 Spring Drill Program The Phase 3 program comprised six diamond drill holes totalling 3,187 metres, following the successful identification of a new gold-bearin

    Newsfile Corp ·

  10. Auranova Announces Closing of Private Placement of Flow-Through Shares

    Vancouver, British Columbia--(Newsfile Corp. - April 7, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") is pleased to announce that, further to its press release of April 1, 2026, it has closed a non-brokered private through the issuance of 3,061,200 common shares in the capital of the Company issued on a "flow-through" basis (each, a "FT Share") at a price of $0.49 per FT Share for aggregate gross proceeds of $1,499,988 (the "Offering"). All securities issued pursuant

    Newsfile Corp ·

  11. Auranova Resources and Kenorland Minerals Commence Spring Drill Program at South Uchi Project

    Vancouver, British Columbia--(Newsfile Corp. - April 1, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") is pleased to announce that it has collared its first drill hole of the Phase 3 diamond drill program at the South Uchi Project (the "South Uchi Project"), located in the Red Lake District of Ontario and held under option from Kenorland Minerals Limited ("Kenorland"). The first drill hole is a 1.2 km step-out along strike to the west of drill holes 25PADD31 and 25PAD

    Newsfile Corp ·

  12. Auranova Resources and Kenorland Minerals Announce Upcoming 2026 Spring Drill Program at The South Uchi Project, Ontario

    Vancouver, British Columbia--(Newsfile Corp. - March 18, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") is pleased to announce the approval of a Phase 3 diamond drill program at the South Uchi Project (the "Project"), located in the Red Lake District of Ontario and held under an option agreement with Kenorland Minerals Limited ("Kenorland"). 2026 Spring Exploration Program The Spring 2026 exploration program and budget have been approved by Auranova and will include u

    Newsfile Corp ·